-
A case of gamma heavy chain disease: a rare B-cell disorder with successful therapeutic response
Jackson Clark, Ritika Vankina, Swarup Kumar 2022 Oct;
-
Blue toes and monoclonal protein: a rare presentation of monoclonal gammopathy of renal significance and a novel treatment approach
Jackson Clark, Swarup Kumar 2022 Oct;
-
Deep learning identifies morphological changes in whole slide images of treatment-resistant TNBC
Ali Foroughi Pour; Te-Chia Wu; Jan Martinek; Swarup Kumar; Tobias Anzeneder; Stephanie Torkler; Franziska Sommermeyer; Karolina Palucka; Jeffrey Chuang Cancer Research 2022 Feb;(82):P1-02-01
-
Mast Cell Leukemia after t(8,21)AML ; a challenge in diagnosis and treatment
Lakshmi Kolandra, William Baker, Swarup Kumar, Meghana Singh, Adriana Kahn NNECOS annual meeting 2021 2021 Oct;
-
An evaluation of patient workflow in hematology clinics at a university hospital referred for the workup of monoclonal gammopathy of undetermined significance (MGUS)
Swarup Kumar, Radhika B Kulkarni, Gonca Ozcan, Asha Tipirneni, Ritika Vankina, and W. Jeffrey Baker Journal of Clinical Oncology 2021 Oct;39(28):207-207
-
Kirk K, Hooper K, Vankina R, Kumar S. Assessing the Development of Myelodysplastic Syndromes in Patients with Plasma Cell Dyscrasias. Blood (2023) 142 (Supplement 1): 6499.
-
Kolandra L, Bahgat J, Bernstein E, Petricca L, Ibrahim O, Kumar S. Lung cancer screening in the prison population. JCO Oncol Pract 19, 2023 (suppl 11; abstr 114).
-
Kumar S, Clark J, Alvarez‑Soto A, El Warrak S, Kumar S, Braish J, Reddy A. A single‑center treatment sequencing analysis in patients with relapsed/refractory multiple myeloma (RRMM). Clinical Lymphoma, Myeloma & Leukemia, Vol. 23, No. S2, S1-S356, 2023. P-280
-
Kumar S, Hooper K, Clark J, Alvarez‑Soto A, Rounds A. Early outcomes and therapy modification strategies in multiple myeloma patients treated with teclistamab, CD3XBCMA BITE: a single center experience. Clinical Lymphoma, Myeloma & Leukemia, Vol. 23, No. S2, S1-S356, 2023. P-024
-
Kumar S, Kirk K, Hooper , Vankina R. A retrospective assessment of biologically relevant genomic perturbations and variants of unknown significance in a cohort of plasma cell disorder at our institution; a single center experience. Clinical Lymphoma, Myeloma & Leukemia, Vol. 23, No. S2, S1-S356, 2023. P-384.
-
Vankina R, Kirk K, Hooper K, Reddy A, Kumar S. Thrombotic significance in plasma cell disorders: do associated clonal hematopoiesis of indeterminate potential (CHIP) mutations increase the risk? Clinical Lymphoma, Myeloma & Leukemia, Vol. 23, No. S2, S1-S356, 2023. P-102
